Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
Cancer Treatment Reviews · 2024-06 · 127 · 102748
DOI: 10.1016/j.ctrv.2024.102748 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-06. Verfasst von Miguel Muniz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: munizrincon.miguel@mayo.edu. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Antigens, Surface, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Mayo Clinic, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: munizrincon.miguel@mayo.edu.
- Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: cloprinzi@mayo.edu.
- Department of Medical Oncology, Mayo Clinic, Rochester, MN, US. Electronic address: orme.jacob@mayo.edu.
- Department of Internal Medicine, Mayo Clinic, Rochester, MN, US. Electronic address: koch.regina@mayo.edu.
- Department of Urology, Mayo Clinic, Rochester, MN, US. Electronic address: mahmoud.ahmed@mayo.edu.
- Department of Medical Oncology, Mayo Clinic, Jacksonville FL, US. Electronic address: kase.adam@mayo.edu.
Förderung
- NCATS NIH HHS
- Mayo Clinic
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Muniz, M., Loprinzi, C. L., Orme, J. J., Koch, R. M., Mahmoud, A. M., Kase, A. M., Riaz, I. B., Andrews, J. R., Thorpe, M. P., Johnson, G. B., Kendi, A. T., Kwon, E. D., Nauseef, J. T., Morgans, A. K., Sartor, O., & Childs, D. S. (2024). Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treatment Reviews, 127, 102748. https://doi.org/10.1016/j.ctrv.2024.102748
Vancouver
Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, et al. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treatment Reviews. 2024;127:102748. doi:10.1016/j.ctrv.2024.102748
BibTeX
@article{Muniz2024,
author = {Muniz, Miguel and Loprinzi, Charles L and Orme, Jacob J and Koch, Regina M and Mahmoud, Ahmed M and Kase, Adam M and Riaz, Irbaz B and Andrews, Jack R and Thorpe, Matthew P and Johnson, Geoffrey B and Kendi, Ayse T and Kwon, Eugene D and Nauseef, Jones T and Morgans, Alicia K and Sartor, Oliver and Childs, Daniel S},
title = {Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {127},
pages = {102748},
doi = {10.1016/j.ctrv.2024.102748}
}
EUVIMED